4//SEC Filing
Flanagan W. Michael 4
Accession 0001599901-25-000071
CIK 0001599901other
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 6:40 PM ET
Size
6.3 KB
Accession
0001599901-25-000071
Insider Transaction Report
Form 4
Flanagan W. Michael
Chief Scientific Officer
Transactions
- Sale
Common Stock
2025-03-20$31.06/sh−11,780$365,868→ 80,195 total
Footnotes (2)
- [F1]Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 25,000 time-based restricted stock units (RSUs) that vested on March 19, 2025. Those RSUs were initially granted as performance-based restricted stock units (PSUs), and converted to time-based RSUs as a result of a performance objective achieved by the Issuer on September 19, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
- [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.06. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Avidity Biosciences, Inc.
CIK 0001599901
Entity typeother
Related Parties
1- filerCIK 0001841990
Filing Metadata
- Form type
- 4
- Filed
- Mar 20, 8:00 PM ET
- Accepted
- Mar 21, 6:40 PM ET
- Size
- 6.3 KB